{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:05:36Z","timestamp":1790827536738,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T00:00:00Z","timestamp":1671062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T00:00:00Z","timestamp":1671062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["108-2314-B-037-050"],"award-info":[{"award-number":["108-2314-B-037-050"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019756","name":"Kaohsiung Municipal Siaogang Hospital","doi-asserted-by":"publisher","award":["H-108-006"],"award-info":[{"award-number":["H-108-006"]}],"id":[{"id":"10.13039\/100019756","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019756","name":"Kaohsiung Municipal Siaogang Hospital","doi-asserted-by":"publisher","award":["H109-009"],"award-info":[{"award-number":["H109-009"]}],"id":[{"id":"10.13039\/100019756","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011645","name":"Kaohsiung Medical University Chung-Ho Memorial Hospital","doi-asserted-by":"publisher","award":["KMUH107-7R21"],"award-info":[{"award-number":["KMUH107-7R21"]}],"id":[{"id":"10.13039\/501100011645","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011645","name":"Kaohsiung Medical University Chung-Ho Memorial Hospital","doi-asserted-by":"publisher","award":["KMUH110-0M22"],"award-info":[{"award-number":["KMUH110-0M22"]}],"id":[{"id":"10.13039\/501100011645","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s40121-022-00734-5","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T16:10:44Z","timestamp":1671120644000},"page":"843-861","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Comparison of Virological Efficacy of DTG\/ABC\/3TG and B\/F\/TAF Regimens and Discontinuation Patterns in Persons Living with Advanced HIV in the Era of Rapid ART: A Retrospective Multicenter Cohort Study"],"prefix":"10.1007","volume":"12","author":[{"given":"Chun-Yuan","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Hsiang","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Jen","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Chin","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Hsun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Pei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Fan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7423-6783","authenticated-orcid":false,"given":"Po-Liang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,15]]},"reference":[{"key":"734_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1468-1293.2010.00857.x","volume":"12","author":"A Antinori","year":"2011","unstructured":"Antinori A, Coenen T, Costagiola D, et al. Late presentation of HIV infection: a consensus definition. HIV Med. 2011;12:61\u20134.","journal-title":"HIV Med"},{"key":"734_CR2","doi-asserted-by":"crossref","unstructured":"IeDEA and COHERE Cohort Collaborations. Global trends in CD4 cell count at the start of antiretroviral therapy: collaborative study of treatment programs. Clin Infect Dis. 2018;66:893\u2013903.","DOI":"10.1093\/cid\/cix915"},{"key":"734_CR3","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s40121-022-00619-7","volume":"11","author":"CY Lee","year":"2022","unstructured":"Lee CY, Lin YP, Wang SF, Lu PL. Late cART initiation consistently driven by late HIV presentation: a multicenter retrospective cohort study in Taiwan from 2009 to 2019. Infect Dis Ther. 2022;11:1033\u201356.","journal-title":"Infect Dis Ther"},{"key":"734_CR4","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1007\/s40265-020-01379-9","volume":"80","author":"KK Scarsi","year":"2020","unstructured":"Scarsi KK, Havens JP, Podany AT, Avedissian SN, Fletcher CV. HIV-1 integrase inhibitors: a comparative review of efficacy and safety. Drugs. 2020;80:1649\u201376.","journal-title":"Drugs"},{"key":"734_CR5","unstructured":"ClinicalInfo. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. 2022. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/whats-new-guidelines. Accessed 03 Aug 2022"},{"key":"734_CR6","unstructured":"EACS Guidelines. 2021. https:\/\/www.eacsociety.org\/media\/final2021eacsguidelinesv11.0_oct2021.pdf. Accessed 03 Aug 2022."},{"key":"734_CR7","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1001\/jama.2020.17025","volume":"324","author":"MS Saag","year":"2020","unstructured":"Saag MS, Gandhi RT, Hoy JF, et al. Antiretroviral drugs for treatment and prevention of hiv infection in adults: 2020 recommendations of the International Antiviral Society-USA Panel. JAMA. 2020;324:1651\u201369.","journal-title":"JAMA"},{"key":"734_CR8","doi-asserted-by":"publisher","first-page":"e355","DOI":"10.1016\/S2352-3018(19)30077-3","volume":"6","author":"DA Wohl","year":"2019","unstructured":"Wohl DA, Yazdanpanah Y, Baumgarten A, et al. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2019;6:e355\u201363.","journal-title":"Lancet HIV"},{"key":"734_CR9","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.1016\/S2352-3018(19)30080-3","volume":"6","author":"HJ Stellbrink","year":"2019","unstructured":"Stellbrink HJ, Arribas JR, Stephens JL, et al. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2019;6:e364\u201372.","journal-title":"Lancet HIV"},{"key":"734_CR10","doi-asserted-by":"publisher","first-page":"e389","DOI":"10.1016\/S2352-3018(20)30099-0","volume":"7","author":"C Orkin","year":"2020","unstructured":"Orkin C, DeJesus E, Sax PE, et al. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials. Lancet HIV. 2020;7:e389\u2013400.","journal-title":"Lancet HIV"},{"key":"734_CR11","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","volume":"390","author":"J Gallant","year":"2017","unstructured":"Gallant J, Lazzarin A, Mills A, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017;390:2063\u201372.","journal-title":"Lancet"},{"key":"734_CR12","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1093\/jac\/dkx053","volume":"72","author":"J Pe\u00f1afiel","year":"2017","unstructured":"Pe\u00f1afiel J, de Lazzari E, Padilla M, et al. Tolerability of integrase inhibitors in a real-life setting. J Antimicrob Chemother. 2017;72:1752\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"734_CR13","doi-asserted-by":"publisher","first-page":"ofac018","DOI":"10.1093\/ofid\/ofac018","volume":"9","author":"K Mounzer","year":"2022","unstructured":"Mounzer K, Brunet L, Fusco JS, et al. Advanced HIV infection in treatment-na\u00efve individuals: effectiveness and persistence of recommended 3-drug regimens. Open Forum Infect Dis. 2022;9:ofac018.","journal-title":"Open Forum Infect Dis"},{"key":"734_CR14","doi-asserted-by":"publisher","first-page":"32","DOI":"10.7326\/M14-2979","volume":"163","author":"OA Uthman","year":"2015","unstructured":"Uthman OA, Okwundu C, Gbenga K, et al. Optimal timing of antiretroviral therapy initiation for HIV-infected adults with newly diagnosed pulmonary tuberculosis: a systematic review and meta-analysis. Ann Intern Med. 2015;163:32\u20139.","journal-title":"Ann Intern Med"},{"key":"734_CR15","doi-asserted-by":"publisher","first-page":"e2134","DOI":"10.1093\/cid\/ciaa1614","volume":"73","author":"A Pyngottu","year":"2021","unstructured":"Pyngottu A, Scherrer AU, Kouyos R, et al. Predictors of virological failure and time to viral suppression of first-line integrase inhibitor-based antiretroviral treatment. Clin Infect Dis. 2021;73:e2134\u201341.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"734_CR16","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1097\/01.qai.0000286599.38431.ef","volume":"46","author":"C Manzardo","year":"2007","unstructured":"Manzardo C, Zaccarelli M, Ag\u00fcero F, Antinori A, Mir\u00f3 JM. Optimal timing and best antiretroviral regimen in treatment-naive HIV-infected individuals with advanced disease. J Acquir Immune Defic Syndr. 2007;46(Suppl 1):S9-18.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"734_CR17","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1586\/14787210.2015.1029917","volume":"13","author":"C Manzardo","year":"2015","unstructured":"Manzardo C, Guardo AC, Letang E, Plana M, Gatell JM, Miro JM. Opportunistic infections and immune reconstitution inflammatory syndrome in HIV-1-infected adults in the combined antiretroviral therapy era: a comprehensive review. Expert Rev Anti Infect Ther. 2015;13:751\u201367.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"734_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2020.104534","volume":"130","author":"D Armenia","year":"2020","unstructured":"Armenia D, Bouba Y, Gagliardini R, et al. Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings. J Clin Virol. 2020;130:104534.","journal-title":"J Clin Virol"},{"key":"734_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212744","volume":"14","author":"MG de Melo","year":"2019","unstructured":"de Melo MG, Varella I, Gorbach PM, et al. Antiretroviral adherence and virologic suppression in partnered and unpartnered HIV-positive individuals in southern Brazil. PLoS ONE. 2019;14:e0212744.","journal-title":"PLoS ONE"},{"key":"734_CR20","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/phar.1728","volume":"36","author":"S Scott Sutton","year":"2016","unstructured":"Scott Sutton S, Magagnoli J, Hardin JW. Impact of pill burden on adherence, risk of hospitalization, and viral suppression in patients with HIV infection and AIDS receiving antiretroviral therapy. Pharmacotherapy. 2016;36:385\u2013401.","journal-title":"Pharmacotherapy"},{"key":"734_CR21","doi-asserted-by":"publisher","first-page":"e003028","DOI":"10.1136\/bmjopen-2013-003028","volume":"3","author":"CJ Cohen","year":"2013","unstructured":"Cohen CJ, Meyers JL, Davis KL. Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US Medicaid population with HIV. BMJ Open. 2013;3:e003028.","journal-title":"BMJ Open"},{"key":"734_CR22","unstructured":"Taiwan Accreditation Foundation. 2021. https:\/\/www.taftw.org.tw\/en\/aboutTAF\/introduction\/. Accessed 3 Aug 2022."},{"key":"734_CR23","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1089\/apc.2020.0044","volume":"34","author":"CY Lee","year":"2020","unstructured":"Lee CY, Wu PH, Tsai JJ, Chen TC, Chang K, Lu PL. Cascade analysis of anonymous voluntary HIV counseling and testing among patients with HIV infection in Taiwan. AIDS Patient Care STDS. 2020;34:303\u201315.","journal-title":"AIDS Patient Care STDS"},{"key":"734_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0179870","volume":"12","author":"KY Lin","year":"2017","unstructured":"Lin KY, Cheng CY, Li CW, et al. Trends and outcomes of late initiation of combination antiretroviral therapy driven by late presentation among HIV-positive Taiwanese patients in the era of treatment scale-up. PLoS ONE. 2017;12:e0179870.","journal-title":"PLoS ONE"},{"key":"734_CR25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/hiv.12962","volume":"22","author":"G Schuettfort","year":"2021","unstructured":"Schuettfort G, Boekenkamp L, Cabello A, et al. Antiretroviral treatment outcomes among late HIV presenters initiating treatment with integrase inhibitors or protease inhibitors. HIV Med. 2021;22:47\u201353.","journal-title":"HIV Med"},{"key":"734_CR26","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/COH.0000000000000468","volume":"13","author":"V Spagnuolo","year":"2018","unstructured":"Spagnuolo V, Castagna A, Lazzarin A. Bictegravir. Curr Opin HIV AIDS. 2018;13:326\u201333.","journal-title":"Curr Opin HIV AIDS"},{"key":"734_CR27","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1097\/QAD.0b013e32834a1dd9","volume":"25","author":"S Min","year":"2011","unstructured":"Min S, Sloan L, DeJesus E, et al. Antiviral activity, safety, and pharmacokinetics\/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS. 2011;25:1737\u201345.","journal-title":"AIDS"},{"issue":"Suppl 1","key":"734_CR28","doi-asserted-by":"publisher","first-page":"S548","DOI":"10.1093\/ofid\/ofaa439.1222","volume":"7","author":"JPWX Cohen","year":"2020","unstructured":"Cohen JPWX, Wade RL, Cuervo HD, Dionne DM. Persistence of guideline-recommended antiretroviral therapy regimens among persons living with HIV newly initiating treatment in the US. Open Forum Infect Dis. 2020;7(Suppl 1):S548-549.","journal-title":"Open Forum Infect Dis"},{"key":"734_CR29","unstructured":"Sutton S WX, Diaz-Cuervo H, Magagnoli J. Persistence of antiretroviral therapy regimens among veterans with HIV newly initiating treatment in the US. In: International Congress on Drug Therapy in HIV Infection, Glasgow; 2020."},{"key":"734_CR30","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1080\/25787489.2021.1965757","volume":"22","author":"F Lagi","year":"2021","unstructured":"Lagi F, Botta A, Ciccullo A, et al. Early discontinuation of DTG\/ABC\/3TC and BIC\/TAF\/FTC single-tablet regimens: a real-life multicenter cohort study. HIV Res Clin Pract. 2021;22:96\u2013101.","journal-title":"HIV Res Clin Pract"},{"key":"734_CR31","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3390\/v14010163","volume":"14","author":"A Ciccullo","year":"2022","unstructured":"Ciccullo A, Baldin G, Borghi V, et al. Real-life impact of drug toxicity on dolutegravir tolerability: clinical practice data from a multicenter Italian cohort. Viruses. 2022;14:163.","journal-title":"Viruses"},{"key":"734_CR32","doi-asserted-by":"publisher","first-page":"68","DOI":"10.18433\/J39S3T","volume":"18","author":"W Tangamornsuksan","year":"2015","unstructured":"Tangamornsuksan W, Lohitnavy O, Kongkaew C, et al. Association of HLA-B*5701 genotypes and abacavir-induced hypersensitivity reaction: a systematic review and meta-analysis. J Pharm Pharm Sci. 2015;18:68\u201376.","journal-title":"J Pharm Pharm Sci"},{"key":"734_CR33","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1056\/NEJMoa0706135","volume":"358","author":"S Mallal","year":"2008","unstructured":"Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358:568\u201379.","journal-title":"N Engl J Med"},{"key":"734_CR34","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/jac\/dkm243","volume":"60","author":"HY Sun","year":"2007","unstructured":"Sun HY, Hung CC, Lin PH, et al. Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan. J Antimicrob Chemother. 2007;60:599\u2013604.","journal-title":"J Antimicrob Chemother"},{"key":"734_CR35","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/hiv.12468","volume":"18","author":"C Hoffmann","year":"2017","unstructured":"Hoffmann C, Welz T, Sabranski M, et al. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med. 2017;18:56\u201363.","journal-title":"HIV Med"},{"key":"734_CR36","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1089\/aid.2020.0078","volume":"37","author":"A Ciccullo","year":"2021","unstructured":"Ciccullo A, Baldin G, Borghi V, et al. Overall tolerability of integrase inhibitors in clinical practice: results from a multicenter Italian cohort. AIDS Res Hum Retroviruses. 2021;37:4\u201310.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"734_CR37","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1136\/sextrans-2020-054821","volume":"97","author":"A Allen Reeves","year":"2021","unstructured":"Allen Reeves A, Fuentes AV, Caballero J, Thomas JE, Mosley Ii JF, Harrington C. Neurotoxicities in the treatment of HIV between dolutegravir, rilpivirine and dolutegravir\/rilpivirine: a meta-analysis. Sex Transm Infect. 2021;97:261\u20137.","journal-title":"Sex Transm Infect"},{"key":"734_CR38","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1080\/14740338.2021.1931115","volume":"20","author":"A Ciccullo","year":"2021","unstructured":"Ciccullo A, Baldin G, Putaggio C, Di Giambenedetto S, Borghetti A. Comparative safety review of recommended, first-line single-tablet regimens in patients with HIV. Expert Opin Drug Saf. 2021;20:1317\u201332.","journal-title":"Expert Opin Drug Saf"},{"key":"734_CR39","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s40271-018-0322-8","volume":"11","author":"D Wohl","year":"2018","unstructured":"Wohl D, Clarke A, Maggiolo F, et al. Patient-reported symptoms over 48 weeks among participants in randomized, double-blind, phase III non-inferiority trials of adults with HIV on co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus co-formulated abacavir, dolutegravir, and lamivudine. Patient. 2018;11:561\u201373.","journal-title":"Patient"},{"key":"734_CR40","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1089\/apc.2015.0199","volume":"30","author":"HB Krentz","year":"2016","unstructured":"Krentz HB, Gill MJ. The impact of non-antiretroviral polypharmacy on the continuity of antiretroviral therapy (ART) among HIV patients. AIDS Patient Care STDS. 2016;30:11\u20137.","journal-title":"AIDS Patient Care STDS"},{"key":"734_CR41","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1089\/apc.2020.0246","volume":"35","author":"CY Lee","year":"2021","unstructured":"Lee CY, Wu PH, Chen TC, Lu PL. Changing pattern of chemsex drug use among newly diagnosed HIV-positive Taiwanese from 2015 to 2020 in the era of treat-all policy. AIDS Patient Care STDS. 2021;35:134\u201343.","journal-title":"AIDS Patient Care STDS"},{"key":"734_CR42","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1177\/0956462420959169","volume":"32","author":"B Funke","year":"2021","unstructured":"Funke B, Spinner CD, Esser S, et al. High prevalence of recreational and illicit drug use in German people living with HIV with a potential for drug-drug interactions with antiretroviral therapy. Int J STD AIDS. 2021;32:75\u201382.","journal-title":"Int J STD AIDS"}],"updated-by":[{"DOI":"10.1007\/s40121-023-00764-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T00:00:00Z","timestamp":1676505600000}}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-022-00734-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-022-00734-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-022-00734-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T14:09:57Z","timestamp":1728569397000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-022-00734-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,15]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["734"],"URL":"https:\/\/doi.org\/10.1007\/s40121-022-00734-5","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40121-023-00764-7","asserted-by":"object"}]},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,15]]},"assertion":[{"value":"14 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40121-023-00764-7","URL":"https:\/\/doi.org\/10.1007\/s40121-023-00764-7","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}